NICE gives final 'no' to Celgene's Otezla; Alvogen launches generic patch for Alzheimer's;

@FiercePharma: Pharma market bets on ASEAN in focus ahead of economic pact. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: Last week, Novo announced huge production build-up. This week a warehouse for the raw materials. More from FiercePharmaManutacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI yesterday: Novartis finally gets to roll out inaugural biosim Zarxio. What will payers and docs do? More | Follow @CarlyHFierce

> The U.K.'s cost watchdogs have issued final draft guidance shooting down Celgene's ($CELG) Otezla in psoriatic arthritis. Release

> Sanofi's ($SNY) Genzyme unit has agreed to pay $32.59 million, admit wrongdoing and enter a deferred prosecution agreement to resolve U.S. criminal charges over its marketing of the surgical implant Seprafilm, used in laparotomies. Story

> Alvogen has launched the first generic equivalent of Exelon patch in the U.S. for treatment of mild to moderate dementia of the Alzheimer's type and mild to moderate dementia associated with Parkinson's disease. Release

Medical Device News

@FierceMedDev: Focus Diagnostics gets FDA blessing to expand label for herpes test. FierceDiagnostics story | Follow @FierceMedDev

@StacyALawrence: Philips unveils consumer, connected health bid featuring app and 5 devices, including watch. Story | Follow @StacyALawrence

@EmilyWFierce: Report: C.R. Bard downplayed serious problems related to blood-clot device. Article | Follow @EmilyWFierce

> Tornier, Wright merger to close soon after foot and ankle implant divestiture. Report

> Allergan to grab AqueSys for $300M+ to add minimally invasive glaucoma microshunt. Story

> Stryker closing South Carolina surgical equipment manufacturing facility. More

Biotech News

@FierceBiotech: The 2015 Fierce 15 will be announced in a few weeks. Celebrate the winners with us in October at #BIF15. More | Follow @FierceBiotech

@JohnCFierce: Fibrodysplasia ossificans progressive gets my vote as one of the world's creepiest deadly diseases. Tissue to bone. More | Follow @JohnCFierce

@DamianFierce: | Follow @DamianFierce

> Roche gets a 'breakthrough' at the FDA for a top PhIII development effort. Article

> Alexion runs into an FDA delay with its latest rare disease drug. Story

> FierceBiotech Radio on Valeant's fantasy football M&A, the gathering PCSK9 storm, and Novartis' alarming new campaign. Listen

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.